True Wealth Design’s NewAmsterdam Pharma NAMS Stock Holding History

True Wealth Design’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$511	Hold	21	–	–	﹤0.01%	2125
2026 Q2	$712	Hold	21	–	–	﹤0.01%	2094
2026 Q1	$673	Hold	21	–	–	﹤0.01%	1942
2025 Q4	$737	Hold	21	–	–	﹤0.01%	1825
2025 Q3	$598	Hold	21	–	–	﹤0.01%	1950
2025 Q2	$381	Buy	21 +19	+950%	+$347	﹤0.01%	1847
2025 Q1	$41	Buy	+2	New	+$44	﹤0.01%	2434

Other funds holding NAMS

TSMHT

Thurston Springer Miller Herd & Titak Indianapolis, Indiana $61.1M AUM 22.51% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

True Wealth Design's NAMS Position: Q3 2026 in Review

True Wealth Design held its NewAmsterdam Pharma (NAMS) position steady in Q3 2026 at 21 shares worth $511. The position accounts for ﹤0.01% of the portfolio, ranked #2125.

True Wealth Design first reported a position in NAMS in Q1 2025 and has held it in 7 quarters since. The position peaked at $737 in Q4 2025. 4 funds tracked by Wall St. Rank hold NAMS as of Q3 2026.

True Wealth Design held 21 shares of NewAmsterdam Pharma worth $511 as of Q3 2026.
True Wealth Design left its NewAmsterdam Pharma share count unchanged in Q3 2026.
NewAmsterdam Pharma made up ﹤0.01% of True Wealth Design's portfolio in Q3 2026, its #2125 holding.
True Wealth Design first reported a position in NewAmsterdam Pharma in Q1 2025 and has held it in 7 quarters since.
True Wealth Design's NewAmsterdam Pharma position peaked at $737 in Q4 2025.
4 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.